Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CytomX Therapeutics (CTMX) Return on Sales (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Return on Sales for 12 consecutive years, with 2.39% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Sales fell 256.0% year-over-year to 2.39%, compared with a TTM value of 0.25% through Sep 2025, up 14.0%, and an annual FY2024 reading of 0.23%, up 24.0% over the prior year.
  • Return on Sales was 2.39% for Q3 2025 at CytomX Therapeutics, down from 0.01% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.5% in Q4 2024 and bottomed at 9.28% in Q4 2022.
  • Average Return on Sales over 5 years is 1.47%, with a median of 0.26% recorded in 2024.
  • The sharpest move saw Return on Sales crashed -615bps in 2022, then surged 931bps in 2023.
  • Year by year, Return on Sales stood at 3.13% in 2021, then crashed by -197bps to 9.28% in 2022, then surged by 100bps to 0.03% in 2023, then skyrocketed by 1475bps to 0.5% in 2024, then crashed by -582bps to 2.39% in 2025.
  • Business Quant data shows Return on Sales for CTMX at 2.39% in Q3 2025, 0.01% in Q2 2025, and 0.46% in Q1 2025.